CNS-242

CNS-242 is an orally active small molecule inhibitor of the urate transporter 1 (URAT1), developed by Nissui for the management of hyperuricemia and gout. By targeting URAT1 (encoded by the SLC22A12 gene) in the proximal tubule of the kidney, CNS-242 inhibits the reabsorption of uric acid from the renal filtrate, thereby promoting its excretion and reducing serum urate levels. The compound reached Phase II clinical development, where it was studied in a multicenter, randomized, double-blind trial in the United Kingdom to evaluate its efficacy and safety in patients with gout. Despite its clinical progress, recent company updates have focused primarily on its eicosapentaenoic acid (EPA) portfolio, leaving the current status of the CNS-242 program unclear.